News

Explore the latest insights, updates, and breakthroughs in cryopreservation and Pentahibe innovation.

2025-11-06|3

Lowering DMSO, Lowering Risk: Why Safety in Cryopreservation Should Never Be Compromised

Research shows that reducing DMSO from 10% to 5% dramatically lowers infusion-related adverse events—without affecting engraftment. At Pentahibe, this is our mission: safe and efficient cryopreservation with no compromise.

2025-09-04|3

Collaboration with InVitria Delivers Strong T Cell Outcomes in Animal-Origin-Free Cryopreservation

Pharmacosmos and InVitria introduce an animal-origin-free cryopreservation strategy for T cells, combining Pentahibe® Base and Optibumin® 25 to deliver strong results with just 2% DMSO.

2025-06-09|3

Breakthrough in Tissue Cryopreservation for Organoid Generation

Can organoid success start with cryopreservation?
Discover how Pentahibe Complete enabled 100% organoid establishment from preserved biopsies, in collaboration with the Cambridge Stem Cell Institute.

2025-04-20|3

Pharmacosmos Leads the Way Toward Safe and Efficient Cryopreservation with Pentahibe

Is it time to move beyond DMSO?
Discover how Pharmacosmos is shaping the future of safe, efficient cryopreservation with Pentahibe — a next-gen, biocompatible solution for cells, tissues, and organoids.

Evidence of Pentahibe performance
Explore Pentahibe Complete's key data

Ready-to-use cryopreservation solution for cell & gene therapies and organoid generation

©2025 PHARMACOSMOS A/S
  • Pharmacosmos A/S
  • Roervangsvej 30
  • DK-4300 Holbaek
  • Denmark
www.pharmacosmos.com